Aspire Biopharma Holdings, Inc. Common Stock
Here’s whether Aspire Biopharma Holdings, Inc. Common Stock (ASBP) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-21.26% over 10 days); RSI 12 — oversold; weak 1-year return of -98.5%; 3-month momentum negative (-87.5%); rising volume on a downtrend (distribution, 2.76x avg). Currently 99.4% off its 52-week high. Score: -7/7.
ASBP is trading below its 200-day MA ($7.92) — a key warning sign the longer-term trend is under pressure. An RSI of 12.3 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -98.5% compares to +24.4% for SPY (trailed the market by 122.9%). The current 99.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.